AdaptHealth expects 8% to 10% growth in 2023

PLYMOUTH MEETING, Pa. – AdaptHealth Corp. is providing initial full year 2023 guidance of $3.21 billion to $3.29 billion in net revenue and adjusted EBITDA of $690 million to $750 million. 

The guidance reflects anticipated net impacts from scheduled changes in the reimbursement and regulatory environment, including increased revenue related to the consumer price index updates to the DMEPOS fee schedule, the extension of current rural and non-rural/non-CBA blended Medicare rates and the extension of sequester relief in 2023. 

“We are pleased with our guidance for the full year ending Dec. 31, 2023, which reflects continued improvement and stabilization of the supply of PAP devices for our sleep business and overall non-acquired net revenue growth for the company in the range of 8% to 10%,” said Steve Griggs, CEO. “Demand remains very strong across our businesses, and we are pleased with our ability to execute on that demand, addressing the needs of our patients and adding value for our partners. We continue to work on innovative technology solutions that allow us to seamlessly communicate with patients, providers and payers to take advantage of value-based care and chronic care management opportunities.” 

AdaptHealth expects net revenue to be near the midpoint of the previously-provided guidance range of $2.950 billion to $3.010 billion for full year 2022. It expects adjusted EBITDA to be near the low end of the previously provided guidance range of $620 million to $650 million. 

The company will release its fourth quarter and full year financial results on Feb. 28. 

• Read about how AdaptHealth had a record number of CPAP setups in the third quarter, but they were offset by a loss in resupply revenue and increased costs.